May 13, 2021
May 13, 2021 – Vera Therapeutics, Inc. (“Vera”), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, announced the pricing of its initial public offering of 4,350,000 shares of its Class A common stock at a price to the public of $11.00 per share. The gross proceeds to Vera from the offering, before deducting the underwriting discounts and commissions and offering expenses, were $47.85 million. All of the shares were offered by Vera. In addition, Vera granted the underwriters a 30-day option to purchase up to an additional 652,500 shares of its Class A common stock at the initial public offering price, less the underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Market on May 14, 2021, under the ticker symbol “VERA.” FLG partner Jonathan Wolter assisted.
Full press release is here.